000			02027 a2200541 4500
005			20250517221835.0
264		0	_c20190408
008			201904s 0 0 eng d
022			_a1474-5488
024	7		_a10.1016/S1470-2045(18)30354-1 _2doi
040			_aNLM _beng _cNLM
100	1		_aMoreau, Philippe
245	0	0	_aOnce weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. _h[electronic resource]
260			_bThe Lancet. Oncology _c07 2018
300			_a953-964 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aDexamethasone _xtherapeutic use
650	0	4	_aDisease-Free Survival
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Administration Schedule
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aInfusions, Intravenous
650	0	4	_aLenalidomide _xtherapeutic use
650	0	4	_aMale
650	0	4	_aMultiple Myeloma _xdrug therapy
650	0	4	_aNeoplasm Invasiveness _xpathology
650	0	4	_aNeoplasm Staging
650	0	4	_aOligopeptides _xtherapeutic use
650	0	4	_aPrognosis
650	0	4	_aProteasome Inhibitors _xtherapeutic use
650	0	4	_aRecurrence
650	0	4	_aRisk Assessment
650	0	4	_aSurvival Analysis
650	0	4	_aTreatment Outcome
700	1		_aMateos, Maria-Victoria
700	1		_aBerenson, James R
700	1		_aWeisel, Katja
700	1		_aLazzaro, Antonio
700	1		_aSong, Kevin
700	1		_aDimopoulos, Meletios A
700	1		_aHuang, Mei
700	1		_aZahlten-Kumeli, Anita
700	1		_aStewart, A Keith
773	0		_tThe Lancet. Oncology _gvol. 19 _gno. 7 _gp. 953-964
856	4	0	_uhttps://doi.org/10.1016/S1470-2045(18)30354-1 _zAvailable from publisher's website
999			_c28494966 _d28494966